Doubts grow over GlaxoSmithKline's $6 billion capital return plan

LONDON (Reuters) - GlaxoSmithKlinemay ditch a plan to return 4 billion pounds ($6.1 billion) to investors, some analysts believe, as the drugmaker prepares to set out its vision for the reshaped...